Compare FRAF & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRAF | IMRX |
|---|---|---|
| Founded | 1906 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.9M | 265.3M |
| IPO Year | 1995 | 2021 |
| Metric | FRAF | IMRX |
|---|---|---|
| Price | $61.09 | $4.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 13.4K | ★ 2.0M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | ★ 88.84 | 37.75 |
| EPS | ★ 1.48 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.44 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $41.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.50 | $2.87 |
| 52 Week High | $62.84 | $10.08 |
| Indicator | FRAF | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.47 | 45.75 |
| Support Level | $54.80 | $3.95 |
| Resistance Level | $62.84 | $5.36 |
| Average True Range (ATR) | 1.85 | 0.29 |
| MACD | 0.16 | 0.04 |
| Stochastic Oscillator | 77.15 | 65.66 |
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.